- Ticker
- AKBA
- Price
- 1.07
- Stock movement up
- +0.01 (0.94%)
- Company name
- Akebia Ther
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 197.15M
- Ent value
- 449.17M
- Price/Sales
- 0.67
- Price/Book
- 21.10
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 295.56%
- 3 year return
- -31.37%
- 5 year return
- -33.36%
- 10 year return
- -
Last updated: 2023-12-01
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior...
November 8, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
November 8, 2023
iO Charts is a Seeking Alpha partner
DIVIDENDS
AKBA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.67 |
| Price to Book | 21.10 |
| EV to Sales | 1.54 |
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
November 7, 2023
iO Charts is a Seeking Alpha partner
Akebia Therapeutics is awaiting an FDA decision on Vafseo expected in March 2024, supported by positive post-marketing safety data. Learn more on AKBA stock here.
November 3, 2023
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 184.25M |
| EPS (TTM) | -0.50 |
| FCF per share (TTM) | -0.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 292.60M |
| Gross profit (TTM) | 201.62M |
| Operating income (TTM) | -85.30M |
| Net income (TTM) | -92.56M |
| EPS (TTM) | -0.50 |
| EPS (1y forward) | -0.25 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 68.90% |
| Operating margin (TTM) | -29.15% |
| Profit margin (TTM) | -31.63% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 90.47M |
| Net receivables | 39.18M |
| Total current assets | 90.47M |
| Goodwill | 55.05M |
| Intangible assets | 72.08M |
| Property, plant and equipment | 0.00 |
| Total assets | 351.83M |
| Accounts payable | 18.02M |
| Short/Current long term debt | 95.04M |
| Total current liabilities | 124.76M |
| Total liabilities | 342.49M |
| Shareholder's equity | 9.34M |
| Net tangible assets | -117.80M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -73.15M |
| Capital expenditures (TTM) | 114.00K |
| Free cash flow (TTM) | -73.15M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -990.82% |
| Return on Assets | -26.31% |
| Return on Invested Capital | -223.89% |
| Cash Return on Invested Capital | -176.95% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.06 |
| Daily high | 1.09 |
| Daily low | 1.02 |
| Daily Volume | 1.19M |
| All-time high | 29.17 |
| 1y analyst estimate | 1.63 |
| Beta | 0.83 |
| EPS (TTM) | -0.50 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 Mar 2024 |
Downside potential
Loading...
Downside potential data
| AKBA | S&P500 | |
| Current price drop from All-time high | -96.33% | -3.90% |
| Highest price drop | -99.14% | -56.47% |
| Date of highest drop | 29 Nov 2022 | 9 Mar 2009 |
| Avg drop from high | -73.05% | -11.47% |
| Avg time to new high | 407 days | 13 days |
| Max time to new high | 2380 days | 1805 days |
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
October 25, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
September 28, 2023
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
197.15M
Marketcap category
Small-cap
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
204
Website
Investor relations
-
SEC filings
CEO
John P. Butler
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
September 26, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 28, 2023
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 25, 2023
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q2 2023 Earnings Conference Call August 25, 2023 9:00 AM ETCompany ParticipantsMercedes Carrasco - Senior...
August 25, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 24, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 24, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 10, 2023
Akebia Therapeutics plans to resubmit kidney disease drug application, while its stock outperforms S&P 500 and shows promising growth potential. Read why AKBA is a Hold.
August 2, 2023
Akebia Therapeutics is cash poor, has large debt, and its Q2 revenues are unlikely to meet analyst estimates. Read about AKBA's upcoming post-earnings catalysts.
August 2, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
July 18, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
June 20, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
June 13, 2023
iO Charts is a Seeking Alpha partnerNext page